The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help. The interviews webpage also uses YouTube, where subtitles and translations are generated automatically by AI; please be advised to exercise caution when precise interpretation is required. For further support with YouTube, visit YouTube Help.
Why is genetic testing key following an acute myeloid leukemia diagnosis?
Jeffrey Lancet
January 6, 2021
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, Know AML spoke to Jeffrey Lancet, Moffitt Cancer Center, Tampa, US. We asked, Why is genetic testing key following an acute myeloid leukemia diagnosis? Lancet explains the reasons why genetic testing is so important at the time of acute myeloid leukemia diagnosis. He underlines three main reasons: prognostic purposes, choice of the initial therapy, and disease tracking.
To what extent do you agree with the following statements?
Please rate between 1 and 5, with 1 being 'strongly disagree' and 5 being 'strongly agree'.
